Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial

ConclusionMedian OS and 1- and 2-year survival rates were higher with TTFields/TMZ and similar to the entire EF-14 population. About 30% of patients reported skin irritation, a lower rate than seen in the entire EF-14 population. These results demonstrate the efficacy and safety of TTFields in Korean newly diagnosed glioblastoma patients.Clinical TrialsClinicaltrials.gov Identifier: NCT00916409.

Source: Journal of Neuro-Oncology - January 31, 2020 Category: Cancer & Oncology Source Type: research